Next Biomed Therapies Oy

develops bispecific and multispecific therapeutic antibodies based on its patented SH3 scaffold technology.

Next Biomed Therapies Oy is actively looking for new industrial collaborations aimed at development of novel biopharmaceuticals based the drSH3-IgG fusion concept, as well as companies interested in licensing of our drSH3 targeting technology.